The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Just tried to buy 100,000 shares, then 50,000 shares and I'm getting "no quote" for both transactions.
Thought I'd take a few more given the spread is v low and the overall business momentum is promising.
Holding 2.1m shares at present and a long term holder
"Why the drop? rising fuel and labour costs, shortages of plant and spares? Any ideas?"
I'm not aware of any AHT specific news but with a PE ratio of c.29 at the current price, a sub 1% yield, quite a lot of debt and rising interest rates, a war underway in Europe and the US infrastructure investment picture less certain (than it was some time ago) I'd say it's a combination of factors reducing confidence in the stock market generally and AHT specifically.
I still have a holding because taking a long term view, they still have a huge amount of possible market share to capture and the company has proven it can expand profitably.
Indeed.
I first bought AHT many years ago at £3.33 and have bought and sold over the years, always holding some. They still make up a large % of my portfolio. Let's hope they get back to £60+
All sounding positive. Added a few more. Now holding 2.1m shares with a 5+ year time horizon (unless Mr Market gets v v carried away again and then I may well take the profits).
Having been a COO and MD of a small business, John's words are resonating well with me. It takes years to build a business.
Taken from:
Doric Nimrod Air Three Limited, Half-Yearly Financial Report, For the period from 1 April 2021 to 30 September 2021
"All payments by Emirates during the Period and throughout the Lease have been made in accordance with the terms of the Lease. All four of the Company’s Aircraft were put into storage in March 2020. MSNs 132 and 136 are currently stored at DWC. MSNs 133 and 134 have been stored at DXB since July 2021. "
British Gas owner Centrica PLC (LSE:CNA), Melrose Industries PLC (LSE:MRO), Hyundai and Kia have all invested in a fundraising round by a pioneering UK clean hydrogen producer, HiiROC Limited.
https://www.proactiveinvestors.co.uk/companies/news/967584/turquoise-hydrogen-innovator-hiiroc-backed-by-string-of-heavyweights-in-new-funding-round-967584.html
MAXCYTE REVENUE JUMPS MORE THAN 50PC IN THIRD QUARTER (from 11 Nov)
Commercial cell engineering company MaxCyte reported total third quarter revenue of $10.1m in an update on Thursday, representing 50% growth compared to the same period in 2020.
The AIM-traded firm said that, excluding strategic platform license (SPL) programme-related revenue, revenue from cell therapy customers was $6.2million for the three months ended 30 September, which was an increase of 38% year-on-year.
SPL programme-related revenue was $2m, which was the received in any quarter to-date, and compared to $0.3m for the same period in 2020.
Revenue from drug discovery customers was $1.9m in the third quarter, a decrease of 5% compared to the same period in 2020, but up sequentially from the second quarter of 2021.
With the addition of Myeloid Therapeutics, Celularity, Sana Biotechnology and Nkarta signed in the year-to-date, MaxCyte said the total number of SPLs now stood at 15.
"We are pleased to report very strong third quarter results driven by ongoing strength in sales to cell therapy customers and robust SPL programme-related revenue," said president and chief executive officer Doug Doerfler.
"We continue to expand our customer base and increase the number of strategic partnerships, now with 15 SPL agreements in place following the announcement of our agreement with Nkarta in early November.
"The vast majority of our SPL agreements enable MaxCyte to participate in pre-commercial milestones and post-commercial sales-based payments on SPL-related programmes."
Doerfler said the company remained "bullish" around the potential for its SPL partnerships to generate meaningful revenue for the business over the next 12-to-18 months and beyond, as its partners continued to see clinical success.
"We are also making important and strategic investments in our business, expanding our marketing, research and development, and product development capabilities, launching innovative solutions to drive future growth, bolstering our leading internal and field-based cell engineering expertise, expanding our manufacturing capabilities as our customers move closer to commercialization, and adding strong talent across all facets of our business.
"Overall, MaxCyte remains well-positioned to support growing adoption of the 'ExPERT' platform technology for cellular-based research and next-generation therapeutic development."
"Hollywood Bowl Group plc, the UK's largest ten-pin bowling operator, will publish its final results for the twelve months ended 30 September 2021 on Wednesday 15th December 2021."
BERENBERG RAISES TARGET ON HOLLYWOOD BOWL
Analysts at Berenberg raised their target price on ten pin bowling centre operator Hollywood Bowl from 280.0p to 300.0p on Tuesday, stating there was a "strikingly obvious upside" to the stock.
Berenberg thinks the risk-reward profile of buying Hollywood Bowl shares has now very much so skewed to the upside, with sales running at a rate well ahead of 2019 levels.
The German bank highlighted that if the company can maintain even part of that momentum, the earnings upgrades this year will be "enormous".
On the other hand, if it doesn't, Berenberg believes the worst-case scenario for the stock will be that it merely meets its estimates and delivers "nice growth" as shareholders have a strong pipeline of new openings to look forward to.
"Based on the trading statement's guidance for the year-end net cash position, we estimate that Hollywood generated EBITDA in H2 2021 of over £20.0m, which is significantly more than it did in H2 2019 (£17m), despite being closed for the first six weeks of H2 2021. This demonstrates the strength of operational gearing at play," concluded Berenberg, which reiterated its 'buy' rating on the stock.
YamR1man (I was a Fireblade man myself)
I could also tell you of all of the shares I sold too early, didn't buy at all, and how I could have retired etc etc. Oh well - that's what makes this pursuit interesting and challenging
Agreed. AHT was one of the first shares I bought when I started to take investing a bit more seriously. I bought at £3.33 and have bought and sold more along the way, but I've always had a fair chunk of my portfolio and they've done quite well since :-)
This is the key reason I didn't sell any shares when the price spiked i.e the difficulty of buying back in.
I've 2m shares now, built up from c.2p a share up through 5 - 8p and a few beyond. I do regret not selling them when I look back at the gains I could have made, and then I remind myself of the challenges of buying back in.
Anyone else on the AJ Bell webinar this evening? Bogart from Burford is presenting now
DD77 - wise words:
"Locking in profit is never a bad thing, even if you can kick yourself sometimes at what might have been. Best advice I can give is not to get too emotionally attached to a company/share - this clouds your judgement"
It's the number 1 piece of advice my dad had drilled into me after a lifetime (his) of investing..."it's never wrong to take a profit" he'd say and I've certainly being paying more attention to spikes and gains over the last few years and done better for it.
It's all very well to adopt the mantra of being a long term, buy and hold investor, and I broadly am, but if the market gives you a huge spike based on sentiment and short term trading, I think it's a good idea to take some or all of that gain as profit, and reassess when the dust settles.
This is especially true for the US market I've found, where in the past I've missed out gains or sat on a loss for a few years as I missed the spike and then the longer term position has been of relatively poor gains.
Of course, most companies will have their spikes and drops but I'm talking about big spikes (e.g. 100 - 300% over a short time period with little change in business performance or news) not general market movement. Often the buy and hold approach works as most people don't buy back in again and miss out on the future gains, but top slicing helps with that.
I've not sold any ITX yet, but would be something like 20 - 30k better off if I'd sold on the spikes and bought back in, but the issue with ITX is that's a thinly traded share and I've built up a large stake (for me) and buying back that many could be v hard if I get the timing off and sell too soon (ie it spikes, it dips, I sell, and then it takes off again) and as my and others analysis suggests the business has real legs, then I'm happy to be patient, add a few on the dips and build a v good stake now, and reap the rewards in 2- 5 years
Thanks for the news TeesExile
I've certainly been impressed when doing my research and I recently bought another good amount. For once, it's nice to see the broker recommendation and a rise in price being well timed for me!
I'm still down on my holding in my ISA (from pre-MW short attack) and now slightly up in my wife's ISA holding.
In case of a protracted down turn again (I still believe in the v positive long term potential), I'll be selling my wife's holding as soon as I see a few days of drops, so that I can close that position out on a positive return and free up the money for something else, with a plan to buy back in again if / when we see another rise.
There's a lot of opportunity in the market and I've a rather large holding in BUR so I'd rather not have the money tied up in a negative position for what might be months before it moves again (been there several times already)
Hi
I'm not sure either - no news on the HL website. Volumes about 30% higher than average according to the Telegraph website.
Not seen any news though
My guess....General market sell off due to various concerns (travel issues, virus, china tension etc etc) and an "The Equity Development Investor Webinar" taking place at 2.45pm on Thursday 25th March might have led to some additional sales, and they've also had a good run of late, so perhaps some profit taking given both previous points.
I assume once they get to a certain % down on the day stop losses are triggered adding to the downward pressure.
Must admit it's disappointing ....recently bought quite a lot more, but I'm a long investor and I expect the share price will increase again in the coming weeks and months as I think the long term performance looks strong .
The other factor to consider is availability - it's a very small cap business and some days volumes are very low. There have been times when I've not been able to get an order fulfilled for several days at time.
So, yes in some respects I wish I'd banked a large profit when they hit circa 8p but if that initial drop then led to a bounce when I wasn't watching, I could be out of the market for days, unable to buy back in and losing out on a possible run that cost me a lot of lost profit.
Given what I've read, I don't think it's unreasonable to assume this business can double it's current market cap, so very crudely get to a 10 - 12p share price.
But in 5 years time, could they be a £250m market cap company? If the revenues build then eventually the market cap will follow and I don't see it as an unreasonable target to hope for.
They've got the IP protection, revenue model (reoccurring orders from major corporates, which we can see are increasing quickly), and previous R&D work behind them. We've also got v large players like CRODA who already know about them.
I'd love for these to hit 20 - 50p in a matter of weeks, but realistically building a good business takes years, and their market has long lead times for downstream product formulations to change. So, I'll watch with interest and patience.
This reminds me when I bought Ashtead (AHT) at about £3.33 maybe 10 years ago. They hit £38 recently. Lets hope ITX is a similar story of growth.